Marta Fernandez-Llaurado

Vancouver, BC V6H3N1, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Differential Preclinical Efficacy of Combined CDK4/6 and MEK Inhibition in Low-Grade Serous Ovarian Carcinoma Based on KRAS/NF1 Mutational Status.

Differential Preclinical Efficacy of Combined CDK4/6 and MEK Inhibition in Low-Grade Serous Ovarian Carcinoma Based on KRAS/NF1 Mutational Status.

Journal: International journal of molecular sciences

Published: December 13, 2025

Identifying therapeutic targets in low-grade serous ovarian carcinomas with no specific molecular profile.

Identifying therapeutic targets in low-grade serous ovarian carcinomas with no specific molecular profile.

Journal: The Journal of pathology

Published: October 28, 2025

FOLR1 as a therapeutic target in platinum-resistant ovarian carcinoma: unique expression patterns across ovarian carcinoma histotypes and molecular subtypes of low-grade serous carcinoma.

FOLR1 as a therapeutic target in platinum-resistant ovarian carcinoma: unique expression patterns across ovarian carcinoma histotypes and molecular subtypes of low-grade serous carcinoma.

Journal: Journal of gynecologic oncology

Published: August 21, 2024

Molecular Surrogate Subtypes of Ovarian and Peritoneal Low-grade Serous Carcinoma.

Molecular Surrogate Subtypes of Ovarian and Peritoneal Low-grade Serous Carcinoma.

Journal: International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists

Published: June 24, 2024

Ovarian carcinosarcomas: p53 status defines two distinct patterns of oncogenesis and outcomes.

Ovarian carcinosarcomas: p53 status defines two distinct patterns of oncogenesis and outcomes.

Journal: Frontiers in oncology

Published: March 27, 2024

High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma.

High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma.

Journal: Scientific data

Published: March 18, 2024

High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma.

High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma.

Journal: Gynecologic oncology

Published: February 06, 2024

Establishment and validation of preclinical models of SMARCA4-inactivated and ARID1A/ARID1B co-inactivated dedifferentiated endometrial carcinoma.

Establishment and validation of preclinical models of SMARCA4-inactivated and ARID1A/ARID1B co-inactivated dedifferentiated endometrial carcinoma.

Journal: Gynecologic oncology

Published: June 08, 2023

NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition.

NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition.

Journal: Molecular cancer therapeutics

Published: January 03, 2022

Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability.

Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability.

Journal: Cancer research

Published: July 09, 2020

Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes.

Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes.

Journal: Gynecologic oncology

Published: August 23, 2019

Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma.

Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma.

Journal: Gynecologic oncology

Published: August 07, 2019

Showing 1-12 of 12

Last Updated: 09/26/2026